First human tests for new drug targeting blood and immune diseases
NCT ID NCT06797375
Summary
This early-stage study tested the safety and how the body processes multiple doses of a new drug called RLYB116. It involved 16 healthy adults to see how well they tolerated the drug and to measure its levels and effects in the blood. The goal was to gather initial safety data before testing in people with diseases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Brisbane
Brisbane, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.